Immunomodulatory drugs (IMiDs) are thalidomide analogues, which possess pleiotropic anti-
myeloma properties including immune-modulation, anti-angiogenic, anti-inflammatory and …

Over the last two decades, the outcomes for patients with multiple myeloma, a plasma cell
malignancy, have dramatically improved. The development of the immunomodulatory drugs …

Immunomodulatory drugs (IMiDs) have been used in hematologic malignancies for the last
decade. However, the mechanism of action of IMiDs is largely unknown. Here we provide a …

Although immunomodulatory drugs (IMiDs), such as thalidomide, lenalidomide, and
pomalidomide, are widely used in the treatment of multiple myeloma (MM), the molecular …

Immunomodulatory drugs (IMiDs) are effective treatments for patients with multiple myeloma.
IMiDs have pleotropic effects including targeting the myeloma cells directly, and improving …

Despite improvements in disease management, multiple myeloma (MM) remains incurable.
Conventional treatment methods are unsatisfactory, leading to a pattern of regression and …

Thalidomide (Thal) achieves responses even in the setting of refractory multiple myeloma
(MM). Although increased angiogenesis in MM bone marrow and the antiangiogenic effect …

Simple Summary This article provides a comprehensive review of new and emerging
treatment strategies against multiple myeloma that employ precision medicines and/or drugs …

CC-4047 (Actimid) and CC-5013 (Revimid) belong to a class of thalidomide analogs
collectively known as the immunomodulatory drugs (IMiDs), which are currently being …

Thalidomide and immunomodulatory drugs (IMiDs), which target multiple myeloma (MM)
cells and the bone marrow microenvironment, can overcome drug resistance. These agents …